Literature DB >> 2995568

The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease.

G Y Minuk, R W Paul, P W Lee.   

Abstract

Recent evidence suggests that neonatal infection with Reovirus type 3 (Reo-3) may play an important role in the pathogenesis of certain idiopathic cholestatic liver diseases of children. Whether this virus is of pathogenetic importance in similar diseases seen in adults is unclear. In this study, sera from 22 adults with idiopathic cholestatic liver disease (16 primary biliary cirrhosis (PBC) and six primary sclerosing cholangitis (PSC] were tested for antibody to Reo-3 virus by a standard hemagglutination inhibition assay. The results were compared to antibody prevalence in ten adults with various other causes of chronic liver disease and 11 healthy volunteers. Although patients with idiopathic cholestatic liver disease had a high prevalence of anti Reo-3 antibodies (20/22, 91%), similar prevalence rates were found in the two control populations (7/10, 70% in chronic liver disease controls and 11/11, 100% in healthy volunteers). Moreover, the geometric mean titres of antibody to Reo-3 virus were similar in all study groups. While these results do not exclude a pathogenetic role for Reo-3 viral infection, they do imply that some genetic predisposition must exist if Reo-3 infection is truly of pathogenetic importance in idiopathic cholestatic liver disease of adults.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995568     DOI: 10.1002/jmv.1890160108

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Authors:  E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-02-27       Impact factor: 3.167

Review 3.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

4.  Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Authors:  Evanthia Galanis; Svetomir N Markovic; Vera J Suman; Gerard J Nuovo; Richard G Vile; Timothy J Kottke; Wendy K Nevala; Michael A Thompson; Jean E Lewis; Kandelaria M Rumilla; Victoria Roulstone; Kevin Harrington; Gerald P Linette; William J Maples; Matt Coffey; James Zwiebel; Kari Kendra
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

5.  Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Authors:  Elizabeth J Ilett; Montserrat Bárcena; Fiona Errington-Mais; Stephen Griffin; Kevin J Harrington; Hardev S Pandha; Matthew Coffey; Peter J Selby; Ronald W A L Limpens; Mieke Mommaas; Rob C Hoeben; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

6.  Reovirus serotypes elicit distinctive patterns of recall immunity in humans.

Authors:  Renée N Douville; Ruey-Chyi Su; Kevin M Coombs; F Estelle R Simons; Kent T Hayglass
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

7.  Systemic delivery of oncolytic viruses: hopes and hurdles.

Authors:  Mark S Ferguson; Nicholas R Lemoine; Yaohe Wang
Journal:  Adv Virol       Date:  2012-01-31

Review 8.  Naturally occurring reoviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  BMB Rep       Date:  2015-08       Impact factor: 4.778

Review 9.  Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus.

Authors:  Vera Kemp; Rob C Hoeben; Diana J M van den Wollenberg
Journal:  Viruses       Date:  2015-12-24       Impact factor: 5.048

Review 10.  Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.

Authors:  Adil Mohamed; Randal N Johnston; Maya Shmulevitz
Journal:  Viruses       Date:  2015-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.